Management of Parkinson disease: Current treatments, recent advances, and future development

Formulary

Volumn 42, Issue 9, 2007, Pages 529-544

  Lo, Keras ^a   Leung, Kevin ^b   Shek, Allen ^a,c  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b Health Plan of San Joaquin   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BENZATROPINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOT DERIVATIVE; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOCOPHEROL; TOLCAPONE; TRIHEXYPHENIDYL; TRIMETHOBENZAMIDE; UBIDECARENONE; UNINDEXED DRUG;

ABDOMINAL PAIN; AGITATION; ANGINA PECTORIS; ANOREXIA; APPLICATION SITE REACTION; ARTHRALGIA; ASTHENIA; BACKACHE; BALANCE DISORDER; BLURRED VISION; BRADYKINESIA; CHOREA; CHOREIFORM DYSKINESIA; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMPULSIVE BUYING DISORDER; COMPULSIVE GAMBLING; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONVULSION; DELUSION; DEMENTIA; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; DYSTONIA; EDEMA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; FOOD DRUG INTERACTION; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART VALVE REGURGITATION; HUMAN; HYPERKINESIA; HYPERTENSION; HYPOTENSION; IMPULSE CONTROL DISORDER; INFECTION; INSOMNIA; LIVEDO RETICULARIS; LIVER TOXICITY; MEMORY DISORDER; MENTAL DISEASE; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE CRAMP; NAUSEA; NERVE DEGENERATION; NERVOUSNESS; NEUROPROTECTION; ON OFF PHENOMENON; ONSET AGE; ORTHOSTATIC HYPOTENSION; PALLOR; PARKINSON DISEASE; PATIENT CARE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL FIBROSIS; REVIEW; RHABDOMYOLYSIS; RHINORRHEA; RIGIDITY; SEDATION; SEXUAL DEVIATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDE ATTEMPT; SWEATING; SYNCOPE; TABLET FORMULATION; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING; TREMOR; UNPLEASANT DREAM; URINE RETENTION; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; YAWNING;

EID: 35048860925     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223-236.
2. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363:1783-1793.
3. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157:1015-1022.
4. Scheife RT, Schumock GT, Burstein A, Gottwald MD, Luer MS. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health Syst Pharm. 2000;57:953-962.
5. Tuite P, Riss J. Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Investig Drugs. 2003;12:1335-1352.
6. Gelb DJ. Introduction to Clinical Neurology. 2nd ed. Boston, MA: Butterworth-Heinemann; 2000.
7. Factor SA, Weiner WJ. Parkinson's Disease: Diagnosis and Clinical Management. 1st ed. New York, NY: Demos Medical Publishing; 2002.
8. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neurology. 2001;56(11 suppl 5):S1-S88.
9. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology [erratum in Neurology. 2006;67:299]. Neurology. 2006;66:976-982.
10. Facts & Comparisons. http://www.factsandcomparisons.com. Accessed August 7, 2007.
11. First DataBank. http://www.firstdatabank.com. Accessed August 7, 2007.
12. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58:11-17.
13. Pahwa R, Factor SA, Lyons KE, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-995.
14. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology. 1991;41:202-205.
15. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63:969-973.
16. FDA announces voluntary withdrawal of pergolide products. Agency working with product manufacturers [press release]. Washington, DC: US Food and Drug Administration; March 29, 2007. http://www.fda.gov/bbs/topics/news/2007/ new01596.html. Accessed August 7, 2007.
17. Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson's disease: A randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry. 1994;57:903-910.
18. Tasmar [package insert]. Aliso Viejo, CA: Valeant Pharmaceuticals International; 2006.
19. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology. 1998;51:520-525.
20. The Parkinson Study Group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.
21. Azilect [package insert]. Kansas City, MO: Teva Neuroscience, Inc; 2006.
22. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol. 2002;59:1937-1943.
23. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566.
24. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch Neurol. 2005;62:241-248.
25. Rascol O, Brooks DJ, Melamed E, et al; LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): A randomised, double-blind, parallel-group trial. Lancet. 2005;365:947-954.
26. Chen JJ, Ly AV. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm. 2006;63:915-928.
27. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM; Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426-432.
28. Zelapar [package insert]. Costa Mesa, CA: Valeant Pharmaceuticals International; 2006.
29. FDA approves Neupro patch for treatment of early Parkinson's disease [press release]. Washington, DC: US Food and Drug Administration; May 9, 2007. http://www.fda.gov/bbs/topics/news/2007/new01631.html. Accessed August 7, 2007.
30. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272-276.
31. LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68:1262-1267.
32. Neupro now approved in Europe for all stages of Parkinson's disease [press release]. Monheim, Germany: Schwarz Pharma; January 16, 2007. http://www.schwarzpharma.com/sp/n2587/press_releasejanuary_16_2007. Accessed August 7, 2007.
33. LeWitt PA. Clinical trials of neuroprotection for Parkinson's disease. Neurology. 2004;63(7 suppl 2):S23-S31.
34. Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26:719-723.
35. Muller T, Buttner T, Gholipour A, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003;341:201-204.
36. Shults CW, Oakes D, Kieburtz K, et al; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541-1550.
37. The NPNDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68:20-28.
38. Storch A, Jost WH, Vieregge P, et al; for the German Coenzyme Q10 Study Group. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol. 2007;64:938-944.
39. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157:142-149.
40. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66:664-671.
41. Patient enrollment on target in National Institutes of Health phase III Parkinson's disease trial [press release]. Palo Alto, CA: Avicena Group, Inc; July 16, 2007. http://www.avicenagroup.com/news_events/press_releases/ 2007_07_16.php. Accessed August 7, 2007.
42. Prestwick Pharmaceuticals announces acquisition of rights to develop and commercialize lisuride in the U.S. [press release]. Washington, DC: Prestwick Pharmaceuticals, Inc; September 29, 2003. htrp://www.prestwickpharma.com/news/ pr_03_9_29.htm. Accessed August 7, 2007.
43. Lisuride Sub Q. Prestwick Pharmaceuticals website. http://www. prestwickpharma.com/products/pr_lisuridesubq.htm. Acccessed August 7, 2007.
44. B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol. 2006;29:80-86.
45. 1A receptor agonist. Synapse. 2006;60:599-608.
46. SLV308 for treatment of patients with Parkinson's disease experiencing motor fluctuations. Clinical-Trials.gov.http://clinicaltrials.gov/ct/show/ nct00406588?order-1. Accessed August 7, 2007.
47. Pahwa R, Stacy MA, Factor SA, et al; EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108-1115.
48. Stocchi F, Stacy MA, Giorgi L, Earl NL. Safety and tolerability of ropinirole 24-hour prolonged release as adjunctive therapy to L-dopa in patients with Parkinson disease [abstract]. Eur J Neurol. 2006;13(suppl2):221. Poster P2201.
49. Once-daily Requip (ropinirole HCl) XL 24-hour extended-release tablets accepted for filing by U.S. FDA [press release]. London, England: SkyePharma PLC; April 13, 2007. http://ir.skyepharma.com/phoenix.zhtml?c=79810&p=irol- newsarticle&id=984508&highlight=. Accessed August 7, 2007.
50. Fariello RG, McArthur R, Bonsignori A, et al. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J Pharmacol Exp Ther. 1998;285:397-403.
51. Research & drug development: Safinamide. Newron Pharmaceuticals website. http://www.newron.com/safinamide.html. Accessed August 7, 2007.
52. Agnati LF, Ferre S, Lluis C, Franco R, Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev. 2003;55:509-550.
53. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs. 2005;14:729-738.
54. Submission of New Drug Application for istradefylline (KW-6002), an investigational anti-Parkinson's disease drug [press release]. Chiyoda-ku, Tokyo: Kyowa Hakko Kogyo Co, Ltd; April 27, 2006. http://www.kyowa.co.jp/eng/ netext/er070427_02.htm. Accessed August 7, 2007.
55. Results of phase-III clinical studies of an anti-Parkinson's disease drug istradefylline (KW-6002) conducted overseas [press release]. Chiyoda-ku, Tokyo: Kyowa Hakko Kogyo Co, Ltd; March 7, 2006. http://www.kyowa.co.jp/eng/netext/ er060307.htm. Accessed August 7, 2007.
56. Preliminary study shows creatine and minocycline may warrant further study in Parkinson's disease [press release]. Washington, DC: National Institutes of Health; February 23, 2006. http://www.nih.gov/news/pr/feb2006/ ninds-23.htm. Accessed August 7, 2007.
57. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29-38.
58. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356:39-46.